References
- Hart S M, Foroni L. Core binding factor genes and human leukemia. Haematologica 2002; 87: 1307–1323
- Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. Curr Opin Hematol 2009; 16: 92–97
- Mrozek K, Bloomfield C D. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr 2008; 52–57
- Marcucci G, Mrozek K, Ruppert A S, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705–5717
- de Bruijn M F, Speck N A. Core-binding factors in hematopoiesis and immune function. Oncogene 2004; 23: 4238–4248
- Davis J N, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene 2003; 303: 1–10
- Durst K L, Lutterbach B, Kummalue T, et al. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 2003; 23: 607–619
- Kim H G, Kojima K, Swindle C S, et al. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 2008; 111: 1567–1574
- Mrozek K, Marcucci G, Paschka P, et al. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008; 20: 711–718
- Schittenhelm M M, Yee K W, Tyner J W, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 2006; 20: 2008–2014
- James C, Ugo V, Le Couedic J P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
- Baxter E J, Scott L M, Campbell P J, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
- Marková J, Trnková Z, Michková P, et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma 2009; 50: 1448–1460
- Care R S, Valk P J, Goodeve A C, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003; 121: 775–777
- Paschka P, Marcucci G, Ruppert A S, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911
- Schnittger S, Kohl T M, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791–1799